Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegylated G-CSF
- Development stage
- Phase 3
- Lead developer
- Amgen
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Pegylated granulocyte colony-stimulating factor (G-CSF) is a long-acting biologic agent used as supportive care to stimulate the production of neutrophils and reduce the risk of febrile neutropenia in patients undergoing myelosuppressive chemotherapy. It is a pegylated form of recombinant human G-CSF (filgrastim), created by the covalent attachment of a polyethylene glycol (PEG) polymer. This modification increases the hydrodynamic size of the protein, thereby reducing renal clearance and significantly extending its plasma half-life compared to non-pegylated G-CSF. This allows for a single subcutaneous dose per chemotherapy cycle rather than daily injections. The drug acts as an agonist at the G-CSF receptor (CSF3R) on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and activation into mature, functional neutrophils. Common examples include pegfilgrastim and lipegfilgrastim.
- Brand names
- NeulastaLonquexZiextenzoNyvepriaNeulapeg
- Other names
- pegylated granulocyte colony-stimulating factorpeg-G-CSFpegfilgrastimlipegfilgrastimempegfilgrastimmecapegfilgrastim
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on pegylated G-CSF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegylated G-CSF.